Skip to main content

1 Result(s)

within Dulce M. Barrios Remove this filter

and

  1. No Access

    Article

    Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

    Rash develops in approximately 50% of patients receiving alpelisib for breast cancer, often requiring dose modifications. Here, we describe the clinicopathologic, laboratory, and management characteristics of ...

    Diana G. Wang, Dulce M. Barrios… in Breast Cancer Research and Treatment (2020)